IGC Pharma is advancing a new approach to one of the most difficult and exhausting symptoms of Alzheimer’s disease: agitation.
The company’s investigational therapy, IGC-AD1, is now in a Phase 2 clinical study known as the CALMA trial, and early data show meaningful reductions in agitation along with signals that may point to potential cognitive benefits. For families and clinicians who struggle with the limited, often sedating options currently available, the treatment represents a promising development backed by a growing body of clinical and preclinical research.
IGC-AD1 contains a cannabinoid-based active pharmaceutical ingredient designed to address the biological drivers of agitation in Alzheimer’s. According to company materials, the CALMA trial is a randomized, double-blind, placebo-controlled study evaluating both safety and efficacy in patients experiencing agitation in Alzheimer’s dementia. Interim results reported by the company showed clinically and statistically significant reductions in agitation compared to placebo. A separate interim update found improvements in sleep and cognition in the treatment group, an exploratory finding that will require confirmation once the full trial is completed. The company says the study is now past 50% enrollment and expanding across research sites in the United States and Canada.
Beyond symptom relief, IGC Pharma highlights research suggesting that elements of its Alzheimer’s pipeline may affect amyloid, tau, neuroinflammation, and other hallmarks of the disease. While IGC-AD1’s primary focus remains agitation, the company notes that disease-related biological activity provides a rationale for examining long-term effects as clinical data accumulate. Broader research efforts at the company incorporate AI-based discovery tools and a program aimed at advancing additional Alzheimer’s candidates.
Agitation affects a large portion of Alzheimer’s patients and is associated with rapid functional decline, caregiver burnout, and increased institutionalization.
Existing medications often require tradeoffs between symptom control and sedation, falls, or cognitive dulling. IGC Pharma’s goal with IGC-AD1 is to develop a therapy that reduces agitation while maintaining a favorable safety profile, giving patients and caregivers a much-needed option for a symptom that significantly impacts day-to-day life.
IGC Pharma describes itself as a clinical-stage biotechnology company developing treatments for Alzheimer’s and metabolic disorders, with more than 30 patent filings, 12 granted patents, and a pipeline that includes programs focused on amyloid plaques, tau, and neurodegeneration. Its lead program, IGC-AD1, remains on track for full Phase 2 completion in the first half of 2026.
More articles from The Marijuana Herald can be found below.
